KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Net Income (2017 - 2025)

Bionano Genomics' Net Income history spans 7 years, with the latest figure at -$8.5 million for Q3 2025.

  • For Q3 2025, Net Income rose 80.78% year-over-year to -$8.5 million; the TTM value through Sep 2025 reached -$38.6 million, up 71.58%, while the annual FY2024 figure was -$112.0 million, 51.82% up from the prior year.
  • Net Income for Q3 2025 was -$8.5 million at Bionano Genomics, down from -$6.9 million in the prior quarter.
  • Across five years, Net Income topped out at -$3.1 million in Q1 2025 and bottomed at -$112.6 million in Q3 2023.
  • The 5-year median for Net Income is -$30.0 million (2022), against an average of -$29.9 million.
  • The largest annual shift saw Net Income plummeted 253.88% in 2023 before it soared 90.13% in 2025.
  • A 5-year view of Net Income shows it stood at -$22.9 million in 2021, then crashed by 68.53% to -$38.7 million in 2022, then decreased by 13.48% to -$43.9 million in 2023, then soared by 54.15% to -$20.1 million in 2024, then surged by 57.75% to -$8.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Net Income are -$8.5 million (Q3 2025), -$6.9 million (Q2 2025), and -$3.1 million (Q1 2025).